Loading clinical trials...
Loading clinical trials...
This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Affibody
NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT06428396 · Metastatic Breast Cancer
NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more
Sahlgrenska University Hospital
Gothenburg
Karolinska University Hospital
Stockholm
Akademiska Sjukhuset
Uppsala
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions